Best Practice & Research in Clinical Rheumatology

Papers
(The H4-Index of Best Practice & Research in Clinical Rheumatology is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
The importance of functional genomics studies in precision rheumatology106
Novel therapies – IMID Co-morbidities93
Update of imaging in the assessment of axial spondyloarthritis86
CAR T-cell therapy and indications for pediatric rheumatology83
Predicting and preventing clinical psoriatic arthritis63
Raynaud's phenomenon and digital ulceration in systemic sclerosis51
A review of the advances in understanding the genetic basis of spondylarthritis and emerging clinical benefit49
Possible future avenues for myositis therapeutics: DM, IMNM and IBM47
Chimeric antigen receptor T-cell (CAR-T) therapy and other cellular immunotherapy treatments for idiopathic inflammatory myopathies46
Rehabilitation interventions in osteoarthritis45
Epidemiology of rheumatic diseases in tropical populations42
Rheumatic manifestations of HIV/AIDS41
The inequity of global healthcare in pediatric rheumatology37
Environmental factors and rheumatic diseases35
Erratum to “Editorial Board” [Best Pract Res Clin Rheumatol (2025) 102094]34
The communication GAP between patients and clinicians and the importance of patient reported outcomes in Systemic Lupus Erythematosus29
Pathophysiology and immunolgical basis of axial spondyloarthritis29
New age of Lupus Nephritis: Updates in guidelines, biomarkers, and therapies29
Novel therapies in Sjögren’s disease: A systematic review of the literature29
Novel therapies for axial spondyloarthritis and future directions28
Index for PART A26
Oral and maxillofacial manifestations of systemic sclerosis26
Exploring the contribution of genetics on the clinical manifestations of systemic lupus erythematosus26
Potential therapeutic targets of fibrosis in inflammatory rheumatic diseases25
Unmet need in the treatment of polymyalgia rheumatica and giant cell arteritis25
0.07730507850647